Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products based on CAR and T cell receptor (TCR) gene therapy platforms for the treatment of cancer, has further strengthened its TCR product platform and established a European presence through the acquisition of T-Cell Factory B.V. (TCF), a privately held Dutch company, which has been renamed Kite Pharma EU. Founded by preeminent scientists, including Professor Dr. ...